|
市場調査レポート
商品コード
1672769
GLP-1受容体作動薬市場：薬剤クラス別、投与経路別、用途別、流通チャネル別、地域別GLP-1 Receptor Agonist Market, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
カスタマイズ可能
|
|||||||
| GLP-1受容体作動薬市場：薬剤クラス別、投与経路別、用途別、流通チャネル別、地域別 |
|
出版日: 2025年02月19日
発行: Coherent Market Insights
ページ情報: 英文 170 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
GLP-1受容体作動薬の世界市場は、2025年に281億9,000万米ドルと推定され、2032年には635億4,000万米ドルに達すると予測され、2025～2032年までの年間平均成長率（CAGR）は12.3%で成長すると予測されます。
| レポート範囲 | レポート詳細 | ||
|---|---|---|---|
| 基準年 | 2024年 | 2025年の市場規模 | 281億9,000万米ドル |
| 実績データ | 2020～2024年 | 予測期間 | 2025～2032年 |
| 予測期間：2025～2032年のCAGR | 12.30% | 2032年の金額予測 | 635億4,000万米ドル |
GLP-1受容体作動薬は、2型糖尿病治療のための重要な抗糖尿病薬のクラス別です。これらは内因性のグルカゴン様ペプチド-1（GLP-1）の作用を模倣したもので、食後に分泌されるペプチドホルモンであり、グルコース依存的にインスリン分泌を刺激し、グルカゴン分泌を抑制します。これらの薬剤は、GLP-1受容体に結合して活性化することにより、糖尿病患者においてインスリン分泌を誘導し、グルカゴン分泌を抑制し、食欲を抑制して体重減少を促進します。他の薬効分類と比較して優れた血糖コントロール効果と低血糖リスクの低さが魅力的な選択肢となっており、市場の成長を牽引しています。
市場力学
世界のGLP-1受容体作動薬市場の成長は、GLP-1受容体作動薬の優れた治療効果と相まって、世界の糖尿病有病率の増加が牽引しています。肥満の増加は2型糖尿病のリスクを増大させるため、より効果的な治療に対する需要が高まっています。しかし、高い開発コストと厳しい規制当局の承認が市場成長の妨げとなる可能性があります。改良された製剤、柔軟な投与オプション、より長い作用時間、多剤併用などを特徴とする新製品の発売は、成長機会をもたらす可能性があります。開発企業は、臨床適応の拡大や患者の利便性向上のための経口剤開発のために研究開発に投資しています。
本調査の主要特徴
本レポートでは、世界のGLP-1受容体作動薬市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。
また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
本書では、世界のGLP-1受容体作動薬市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
本調査の対象となる主要企業には、Novo Nordisk A/S、Eli Lilly and Company、Sanofiなどが含まれます。
本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関して、情報に基づいた意思決定を行うことができるようになります。
世界のGLP-1受容体作動薬市場レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者を対象としています。
利害関係者は、世界のGLP-1受容体作動薬市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。
目次
第1章 調査の目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
- 一貫型機会マップ（COM）
第3章 市場力学、規制、動向分析
- 市場力学
- 促進要因
- 抑制要因
- 機会
- 影響分析
- 市場動向
- 規制シナリオ
- 買収と提携のシナリオ
- 資金調達と投資
- PEST分析
- ポーターの分析
第4章 世界のGLP-1受容体作動薬市場-コロナウイルス（COVID-19）パンデミックの影響
- 全体的な影響
- 政府の取り組み
- COVID-19による市場への影響
第5章 世界のGLP-1受容体作動薬市場、薬剤クラス別、2020～2032年（10億米ドル）
- イントロダクション
- エキセナチド
- リラグルチド
- デュラグルチド
- リキシセナチド
- アルビグルチド
- セマグルチド
第6章 世界のGLP-1受容体作動薬市場、投与経路別、2020～2032年（10億米ドル）
- イントロダクション
- 非経口
- 経口
第7章 世界のGLP-1受容体作動薬市場、用途別、2020～2032年（10億米ドル）
- イントロダクション
- 2型糖尿病
- 肥満
- 肝硬変
- 非アルコール性脂肪肝炎
- その他
第8章 世界のGLP-1受容体作動薬市場、流通チャネル別、2020～2032年（10億米ドル）
- イントロダクション
- 病院薬局
- 小売薬局
- オンライン薬局
第9章 世界のGLP-1受容体作動薬市場、地域別、2020～2032年（10億米ドル）
- イントロダクション
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第10章 競合情勢
- 企業プロファイル
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis bIoTech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
第11章 アナリストの推奨事項
- 隆盛と衰退
- 一貫型機会マップ
第12章 参考文献と調査手法
- 参考文献
- 調査手法
Global GLP-1 Receptor Agonist Market is estimated to be valued at USD 28.19 Bn in 2025 and is expected to reach USD 63.54 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 28.19 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.30% | 2032 Value Projection: | USD 63.54 Bn |
GLP-1 receptor agonists are an important class of anti-diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon-like peptide-1 (GLP-1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. By binding to and activating the GLP-1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.
Market Dynamics:
Global GLP-1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP-1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi-indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.
Key Features of the Study:
This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global GLP-1 receptor agonist market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market
Detailed Segmentation-
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- Parenteral
- Oral
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Cassiopea
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global GLP-1 Receptor Agonist Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global GLP-1 Receptor Agonist Market, By Drug Class, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Exenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liraglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dulaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lixisenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Albiglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Semaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global GLP-1 Receptor Agonist Market, By Route of Administration, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global GLP-1 Receptor Agonist Market, By Application, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Type 2 Diabetes Mellitus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Obesity
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver Cirrhosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-alcoholic Steatohepatitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global GLP-1 Receptor Agonist Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global GLP-1 Receptor Agonist Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Eli Lilly and Company
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
